Role of pharmacoeconomics in developing countries

Amani Mori, Paul Gavaza, Bjarne Robberstad


Full Text:



  • WHO: Equitable access to essential medicines: a framework for collective action. Geneva: World Health Organization, 2004
  • WHO: The world medicine situation. Geneva: World Health Organization, 2011
  • Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 2009; 373: 240-9;
  • Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. Third edition. New York: Oxford University Press, 2005
  • Hogerzeil HV. The concept of essential medicines: lessons for rich countries. BMJ 2004; 329:1169-1171;
  • Mori AT, Robberstad B. Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review. BMC Med Inform Decis Mak 2012; 12: 110;
  • Gavaza P, Rascati KL, Oladapo AO, et al. The State of Health Economic Research in South Africa: A Systematic Review. Pharmacoeconomics 2012, 30: 925-40;
  • Gavaza P, Rascat KL, Oladapo AO, et al.The State of Health Economic Evaluation Research in Nigeria: A Systematic Review. Pharmacoeconomics 2010, 28: 539-53
  • Gavaza P, Rascati K, Brown C, et al. The state of health economic and pharmacoeconomic evaluation research in Zimbabwe: a review. Current Therapeutic Research 2008; 69: 268-85;
  • Babar Z, Scahill S. Is there a role for pharmacoeconomics in developing countries? Pharmacoeconomics 2010; 28: 1069-74;
  • Pooja RD, Hitesh CS, Rascati KL. Assessing the quality of pharmacoeconomic studies in India: a systematic review. Pharmacoeconomics 2012; 30: 749-62;
  • Tarn YH, Hu S, Kamae I, et al. Health-care systems and pharmacoeconomic research in Asia-Pacific Region. Value in Health 2008; 1(Supp 1): S137-5;
  • Mori AT, Kaale EA. Priority setting for the implementation of artemisinin-based combination therapy policy in Tanzania: evaluation against the accountability for reasonableness framework. Implement Sci 2012; 7: 18;
  • Wiseman V, Kim M, Mutabingwa TK, et al. Cost-effectiveness study of three antimalarial drug combinations in Tanzania. PLoS Med 2006; 3: e373;
  • Chanda P, Masiye F, Chitah BM, et al. A cost-effectiveness analysis of artemether lumefantrine for treatment of uncomplicated malaria in Zambia. Malar J 2007; 6: 21
  • Muheki C, McIntyre D, Barnes KI. Artemisinin-based combination therapy reduces expenditure on malaria treatment in KwaZulu Natal, South Africa. Trop Med Int Health 2004; 9: 959-66;
  • Pillay A. Role of pharmacoeconomics in a developing country context. In International Conference on Improving Use of Medicines. Antalya, Turkey, 2011
  • Abdulla S, Goodman C, Coleman P, et al. The costs, effects and cost-effectiveness of changing the first line drug for treatment of malaria in Tanzania. Health Economics and Financing Program working paper 01/2000


  • There are currently no refbacks.

© SEEd srl